TY - JOUR
T1 - Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma
AU - Personeni, Nicola
AU - Giordano, Laura
AU - Abbadessa, Giovanni
AU - Porta, Camillo
AU - Borbath, Ivan
AU - Daniele, Bruno
AU - Van Laethem, Jean Luc
AU - Van Vlierberghe, Hans
AU - Trojan, Jörg
AU - De Toni, Enrico N.
AU - Gasbarrini, Antonio
AU - Lencioni, Monica
AU - Lamar, Maria E.
AU - Wang, Yunxia
AU - Shuster, Dale
AU - Schwartz, Brian
AU - Santoro, Armando
AU - Rimassa, Lorenza
PY - 2017/1/1
Y1 - 2017/1/1
N2 - The ARQ 197-215 study randomized patients to tivantinib or placebo and prespecified efficacy analyses indicated the predictive value of MET expression as a marker of benefit from tivantinib in hepatocellular carcinoma (HCC). We aimed to explore the neutrophil-to-lymphocyte ratio (NLR) in 98 ARQ 197-215 patients with available absolute neutrophil count and absolute lymphocyte count at baseline. The cut-off value used to define high versus low NLR was 3.0. In univariate analysis, high NLR was associated with hazard ratio (HR) for overall survival (OS) of 1.58 [95% confidence interval (CI) 1.01; 2.47; P < 0.046], corresponding to median OS of 5.1 months versus 7.8 months in patients with low NLR (P = 0.044). In contrast, time to progression was not significantly affected by NLR (P = 0.20). Multivariable model confirmed that both NLR >3 (P = 0.03) and presence of vascular invasion (P = 0.017) were negatively associated with OS. After adjustment for vascular invasion, NLR independently predicted survival in both the placebo and the tivantinib cohort. For OS, no interaction was detected between NLR status and treatment (Pinteraction = 0.40). Baseline NLR is an independent prognostic biomarker in patients with HCC and compensated liver function who are candidate for second-line treatments.
AB - The ARQ 197-215 study randomized patients to tivantinib or placebo and prespecified efficacy analyses indicated the predictive value of MET expression as a marker of benefit from tivantinib in hepatocellular carcinoma (HCC). We aimed to explore the neutrophil-to-lymphocyte ratio (NLR) in 98 ARQ 197-215 patients with available absolute neutrophil count and absolute lymphocyte count at baseline. The cut-off value used to define high versus low NLR was 3.0. In univariate analysis, high NLR was associated with hazard ratio (HR) for overall survival (OS) of 1.58 [95% confidence interval (CI) 1.01; 2.47; P < 0.046], corresponding to median OS of 5.1 months versus 7.8 months in patients with low NLR (P = 0.044). In contrast, time to progression was not significantly affected by NLR (P = 0.20). Multivariable model confirmed that both NLR >3 (P = 0.03) and presence of vascular invasion (P = 0.017) were negatively associated with OS. After adjustment for vascular invasion, NLR independently predicted survival in both the placebo and the tivantinib cohort. For OS, no interaction was detected between NLR status and treatment (Pinteraction = 0.40). Baseline NLR is an independent prognostic biomarker in patients with HCC and compensated liver function who are candidate for second-line treatments.
KW - Hepatocellular carcinoma
KW - MET
KW - Neutrophil-to-lymphocyte ratio
KW - Neutrophils
KW - Tivantinib
UR - http://www.scopus.com/inward/record.url?scp=85014092751&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014092751&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.14797
DO - 10.18632/oncotarget.14797
M3 - Article
AN - SCOPUS:85014092751
VL - 8
SP - 14408
EP - 14415
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 9
ER -